Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
Rhea-AI Summary
Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix technologies, has announced its participation in Chardan's Trending Issues in Drug Development Conference Series. The company's Chief Scientific Officer, Dr. Michelle LeRoux Williams, will join a fireside chat discussion focused on 'Data & Regulatory Catalysts – Navigating an Evolving Landscape' on Tuesday, April 29, 2025, at 11:00 a.m. ET.
The virtual event will be accessible to investors and interested parties through a live webcast, with an archived version available afterward on the company's investor relations website at investors.elutia.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ELUT gained 0.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.
Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – Virtual
Format: Fireside Chat
Date and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)
Webcast: Click Here
A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
This press release was published by a CLEAR® Verified individual.